This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Galectin Therapeutics, Inc. (OTC: GALT), the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis, today announced that Dr. Peter G. Traber, Chief Executive Officer, President and Chief Medical Officer, is scheduled to present a corporate update at the BIO CEO & Investor Conference on Tuesday, February 14, 2012, at 10:30am ET at the Waldorf- Astoria Hotel in New York City.
The presentation will be webcast live at:
http://www.veracast.com/webcasts/bio/ceoinvestor2012/76206188.cfm. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection. The webcast replay will be available for one hour after conclusion of the presentation and will be archived until May 14, 2012.
Dr. Traber plans to update the Company’s corporate strategy and progress towards developing GR-MD-02 for treating liver fibrosis and fatty liver disease. The pre-clinical data show that galectin inhibitor candidate GR-MD-02 reversed fibrosis in mouse models of steatohepatitis and prevented collagen deposits in groups treated before fibrosis was present. The data suggest that patients with non-alcoholic steatohepatitis (NASH), also referred to as fatty liver disease, may benefit from galectin inhibition and that GR-MD-02 could drive a reduction of steatosis, necrosis, inflammation and collagen deposits. Currently, liver transplantation is the only option for patients afflicted with liver fibrosis or cirrhosis, and many times the condition recurs in the patient’s new liver, creating the need for a safer and more efficacious treatment.
Dr. Traber also will present the Company’s progress in its cancer immunotherapy program as The Ludwig Institute of Cancer Research and the Cliniques Universitaires Saint-Luc Cancer Center in Brussels is expected to initiate a Phase 1/2 clinical trial of GM-CT-01 in combination with the Institute’s cancer vaccine in patients with metastatic melanoma. GM-CT-01 has demonstrated robust reactivation of tumor infiltrating T-cells in pre-clinical trials, an exciting new area of cancer immunotherapy.